You are viewing an incomplete version of our website. Please click to reload the website as full version.

C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1) (pTyr245) Peptide

Details for Product No. ABIN693930, Supplier: Login to see New
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Protein Name
Synonyms ABL1, ABL, CABL, ABLL, cb272, JTK7, bcr/abl, c-ABL, p150, v-abl, AI325092, Abl, E430008G22Rik, c-Abl, MTP
Protein Region
Peptide Type Synthetic
Blocking Peptide (BP)
Pubmed 5 references available
Supplier Login to see New
Catalog number from supplier Login to see New
Quantity 0.1 mg
Shipping to United States ( )
Availability Will be delivered in 10 to 11 Business Days
Immunogen Synthetic peptide
Specificity The synthetic peptide sequence used to generate the antibody AP3013a was selected from the region of human Phospho-ABL1-Y245. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Background ABL1 is a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9,22) translocation results in the head-to-tail fusion of the BCR and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1.
Restrictions For Research Use only
Storage 4
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Background publications Barnes, McIntosh, Whetton et al.: "Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation." in: Oncogene, Vol. 24, Issue 20, pp. 3257-67, 2005 (PubMed).

Kim, Cho, Yoon et al.: "Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra ..." in: Genes, chromosomes & cancer, Vol. 43, Issue 1, pp. 37-44, 2005 (PubMed).

Robinson, Martineau, Harris et al.: "Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 19, Issue 4, pp. 564-71, 2005 (PubMed).

Wei, Li, Liu: "Insights into selective activation of p53 DNA binding by c-Abl." in: The Journal of biological chemistry, Vol. 280, Issue 13, pp. 12271-8, 2005 (PubMed).

Aichberger, Mayerhofer, Krauth et al.: "Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides." in: Blood, Vol. 105, Issue 8, pp. 3303-11, 2005 (PubMed).

Catalog No. ABIN693930
Plus shipping costs $45.00

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)